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with chronic left ventricular dysfunction at increased risk for sudden cardiac death as 
compared to current risk stratiﬁcation methods for selection of patients for implanted 
cardiac deﬁbrillators (ICD) versus medical therapy. METHODS: A Markov model 
was developed to evaluate the impact of using AdreView for evaluating NYHA II or 
III heart failure (HF) patients with LV ejection fraction (EF) <50% for treatment with 
an ICD. AdreView risk-stratiﬁcation was used to guide the treatment decision between 
ICD and medical therapy. The source of data for predicted probabilities, expected 
mortality rates, and treatment costs in year 2009 dollars are from the published litera-
ture and the AdreView Myocardial Imaging for Risk Evaluation in Heart Failure 
(ADMIRE-HF) study. The model was developed from a societal perspective using a 
one-month cycle time, 3% discount rate and a lifetime time horizon. Sensitivity analy-
sis was completed on cost, efﬁcacy and relative risk ratios. RESULTS: AdreView had 
an incremental cost-effectiveness ratio (ICER) of $100,910 versus standard stratiﬁca-
tion methods. The number needed to screen to prevent one death over 5 years was 
20. The model was sensitive to changes in utility values ($91,737–$112,123 / QALY), 
efﬁcacy of ICD in low risk patients ($95,805–$107,388 / QALY) and efﬁcacy of ICD 
in high risk patients ($81,578–$166,086 / QALY). The model was not sensitive 
AdreView cost, even at 200% of baseline ($104,068 / QALY). CONCLUSIONS: 
AdreView is a relatively cost-effective screening strategy versus current methods that 
can prevent sudden cardiac deaths within as few as 20 patient screenings. Further 
research on the use of AdreView in real-world settings is warranted.
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OBJECTIVES: Compare the cost-effectiveness of rosuvastatin versus standard man-
agement according to Framingham risk for the primary prevention of vascular events 
in JUPITER-like patients that had LDL levels less than 130 mg/dL and CRP levels of 
2.0 mg/L or higher. METHODS: TreeAge Pro 2009 software was used to design 2 
Markov-type models from a third party payer perspective to calculate the incremental 
cost-effectiveness ratio (ICER) of rosuvastatin 20 mg versus standard management 
over 10 years in patients with a Framingham Risk Score greater than 10% and less 
than or equal to 10%. Cost data were obtained from CMS and the Redbook. Quality 
of life measures were obtained from the literature. Event data were obtained directly 
from the JUPITER Study Group. One-way sensitivity analysis and probabilistic sen-
sitivity analysis were conducted on many possible ranges of cost, quality of life 
measures, and event rates. RESULTS: Treating patients with rosuvastatin to prevent 
vascular events would result in an estimated ICER of $37,232/QALY and $95,000/
QALY in those with Framingham Risk Scores greater than 10%, and less than or 
equal to 10%, respectively. Results of 1-way sensitivity analysis were especially sensi-
tive to the price of the rosuvastatin and the probability of a primary endpoint event 
in the standard management group. Results of a probabilistic sensitivity analysis 
suggest that in patients with a Framingham score greater than 10%, the probability 
that rosuvastatin would be considered cost-effective at a $50,000/QALY threshold is 
approximately 97.5%. In those patients with a Framingham Risk Score less than or 
equal to 10%, the probability that rosuvastatin would be considered cost-effective is 
less than 1%. CONCLUSIONS: Compared with standard management practices, 
statin therapy with rosuvastatin may be a cost-effective strategy over a 10-year time 
horizon for preventing vascular events in patients with a Framingham Risk Score 
greater than 10% that have normal LDL levels and elevated CRP levels.
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PRACTICE IN TURKEY FROM A PAYER PERSPECTIVE
Koçkaya G
Yeditepe University, Istanbul, Turkey
OBJECTIVES: In Turkey, there is Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin 
and Simvastatin in the statin market. And all statins are reimbursed by health insur-
ance companies.The aim of this study is to determine the cost-effective statins which 
are reimbursted by the Social Security Foundation,the biggest reimburestment founda-
tion in Turkey. METHODS: A cost-effectiveness analysis was designed from the 
perspective of the insurance company view. For insurance company data; Social 
Security Foundation which is the biggest reinburstment foundation in Turkey was 
chosen. The assumed treatment protocol depended on the one in the Republic of 
Turkey Health Ministery Primary Care Diagnosis and Treatment Guide which was 
published in 2003.The values of the mean effectiveness of statins are taken from a 
published meta-analysis. RESULTS: Simvastatin had the lowest cost in the ﬁrst year 
of therapy ($166), followed by pravastatin ($300),ﬂuvastatin ($365),rosuvas-
tatin($437) and atorvastatin($448). When the drugs were compared for the incremen-
tal cost-effectiveness, simvastatin dominated pravastatin and ﬂuvastatin,whereas 
rosuvastatin dominated atorvastatin.The ﬁrst year incremental cost of rosuvastatin 
was $271 compared to simvastatin, or $30 per additional 1% reduction in LDL-C, 
$225 per additional 1% increase in HDL-C and $1856 per additional patients to ATP 
II goal. CONCLUSIONS: Because simvastatin had a lower acquisition cost than all 
statins and its all dosages cost approximately 1/3 of the nearest alternative statin, in 
our base case and alternative scenarios simvastatin was the least costly alternative. 
Thus depending on actual acquisition prices and following costs such as doctor visits 
and laboratories the payer may achieve substantial cost savings and greater effective-
ness by using rosuvastatin or simvastatin instead of these agents in Turkey. Therefore, 
simvastatin and rosuvastatin comprise of the optimal two statin formulary. Formulary 
desicion based on these results should be revisited periodically, as new pricing, out-
comes and safety data become available.
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OBJECTIVES: To evaluate the cost-effectiveness of treating patients without tradi-
tional risk factors for cardiovascular disease with statins. METHODS: Cost-effective-
ness was evaluated using a backward induction model. A hypothetical cohort of men 
and women aged 40 to 80 years was evaluated for their ﬁrst acute myocardial infarction 
(AMI) or cardiovascular accident (CVA). The Reynolds Risk Score (RRS) was used to 
generate event risks and risk reductions as the impact of therapy on lipids and c-reactive 
protein (CRP) could be calculated independently. Covariates for the RRS were adapted 
from the JUPITER trial and national health statistics. Life expectancies, quality of life 
adjustments, and event costs for AMI and CVA were ascertained from the primary 
literature. Direct and indirect treatment costs were based on the primary literature, 
Adult Treatment Panel III (ATPII) protocols and the Bureau of Labor Statistics. Medi-
cation costs were adapted from the Federal Supply Schedule. Costs were inﬂated to 
2009 US$ using the medical component of the CPI and discounted at a rate of 3%. A 
sensitivity analysis was also performed. RESULTS: Using a threshold of $150,000 per 
QALY, treatment was cost-effective with generic statins in all men and women, aged 
40 to 80 years when both CRP and LDL levels were affected. It was cost-effective to 
treat men >60 years with a hypothetical medication that only affected CRP levels. In 
the base case (65 year old men/women), the model was sensitive to adherence, smoking 
status (women), premature family history of AMI, brand rosuvastatin price, and the 
level of LDL reduction. CONCLUSIONS: In this population, it is cost-effective to treat 
all patients for the primary prevention of AMI and CVA with a generic statin that 
confers therapeutic beneﬁts similar to what was modeled in this study. Selectively 
lowering CRP levels is only cost-effective in males >60 years.
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OBJECTIVES: A decision-analytic model using cost data and clinical information 
from the PREVAIL study showed that enoxaparin was cost-saving from the payer 
perspective compared with unfractionated heparin (UFH) for the prevention of venous 
thromboembolism (VTE) in patients with acute ischemic stroke (overall costs of clini-
cal events plus drug costs: $2018 vs. $2913, respectively; difference $895 per patient). 
To test the robustness of the cost difference of enoxaparin versus UFH for VTE 
prevention after an acute ischemic stroke, univariate and multivariate sensitivity 
analyses were performed. METHODS: In the univariate analysis, the payer cost 
(2007$) for each clinical event (deep-vein thrombosis [DVT], pulmonary embolism 
[PE]; intracranial hemorrhage [ICH], major extracranial hemorrhage [MjEH] and 
minor extracranial hemorrhage [MnEH]) was adjusted individually, increasing or 
decreasing by 20%, while other parameters (drug costs, event rates) remained 
unchanged. The multivariate analysis was a Monte Carlo simulation (Crystal Ball 
software), where all the parameters were simultaneously varied in a random fashion 
within a range of ± 20% over 10,000 trials. RESULTS: The cost of DVT was $13,499. 
When increased by 20% to $16,199, the difference between UFH and enoxaparin 
groups was $1,104; when decreased by 20% to $10,799, the difference was $686. 
The baseline costs were $20,635 for PE, $26,037 for ICH, $22,765 for MjEH and 
$815 for MnEH. When these were increased by 20%, the difference between enoxa-
parin and UFH groups was $928, $907, $859 and $896, respectively. When decreased 
by 20%, the difference was $862, $883, $932 and $894. Using the Monte Carlo 
simulation multivariate analysis, the difference varied between $615 and $1,177, with 
mean (SD) $896 ($91) and median of $897. Enoxaparin was less costly than UFH 
across all analyses, with DVT being the main cost driver. CONCLUSIONS: Univariate 
and multivariate sensitivity analysis conﬁrmed that enoxaparin is more cost-saving 
than UFH for VTE prevention after an acute ischemic stroke.
PCV76
SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS OF SELECTED 
CARDIAC IMAGING TECHNOLOGIES IN THE DIAGNOSIS OF 
CORONARY ARTERY DISEASE
Machado M1, Witteman W1, Wijeysundera H2, Ieraci L1, van der Velde G3, Paulden M1, 
Krahn M3
1Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, 
Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 3Toronto Health 
Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
OBJECTIVES: To identify, retrieve, and summarize studies evaluating the cost-effec-
tiveness of selected cardiac imaging tests for the diagnosis of CAD. METHODS: 
